Together as a panel, CA9, CYFIP2, and LGALS3BP were able to be used as a multi-gene prognostic index, highlighting the utility of these three molecules for predicting prognoses of glioma patients. The gene discussed is LGALS3BP; the disease is central nervous system cancer.